Posted inClinical Updates Oncology Specialties
Updated Phase III HARMONi Trial Data Reveal Enhanced Survival Benefits of Ivonescimab in NSCLC
Recent updates from the global Phase III HARMONi study demonstrate envafolimab’s significant improvement in overall and progression-free survival in NSCLC, with consistent benefits across diverse populations, reinforcing its emerging role in lung cancer therapy.